Ally Bridge Group NY LLC Makes New $2.53 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Ally Bridge Group NY LLC bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 699,730 shares of the company's stock, valued at approximately $2,533,000. Atyr PHARMA makes up approximately 2.1% of Ally Bridge Group NY LLC's portfolio, making the stock its 22nd biggest holding. Ally Bridge Group NY LLC owned approximately 0.83% of Atyr PHARMA as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. 683 Capital Management LLC purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $898,000. Jane Street Group LLC acquired a new position in shares of Atyr PHARMA in the fourth quarter worth $720,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth $230,000. Northern Trust Corp acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at $661,000. Finally, Oxford Asset Management LLP purchased a new position in Atyr PHARMA in the fourth quarter valued at $115,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ATYR. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an "overweight" rating for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Atyr PHARMA has a consensus rating of "Buy" and an average target price of $18.60.

Atyr PHARMA Stock Performance

ATYR traded down $0.02 on Monday, reaching $3.58. The company had a trading volume of 746,125 shares, compared to its average volume of 904,413. The stock has a market capitalization of $318.12 million, a PE ratio of -3.81 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA INC has a 1 year low of $1.42 and a 1 year high of $4.66. The stock has a 50-day moving average price of $3.29 and a 200-day moving average price of $3.40.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, research analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.